SCHEMBL334040

SCHEMBL334040

O=C(O)C(O)Cc1ncc[nH]1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 2/20 0.47
PTPRA P18433 1/20 0.46
TAAR1 Q96RJ0 5/20 0.42
FDPS P14324 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 2/20 0.39
ALOX15 P16050 1/20 0.39
FPR2 P25090 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
GRIA4 P48058 1/20 0.37
HTR1A P08908 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
KDM6B O15054 1/20 0.36
TERT O14746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9554662 1.00 TBXAS1 (0.47) TBXAS1PTPRATAAR1FDPSSMN1; SMN2
SCHEMBL11456188 0.83 TBXAS1 (0.49) TBXAS1TAAR1FDPSSMN1; SMN2GAA
Histidine SCHEMBL27753697 0.80 GRIA1 (0.39) TBXAS1PTPRASMN1; SMN2ALOX15GRIA1
SCHEMBL5185101 0.80 TBXAS1 (0.46) TBXAS1TAAR1FDPSSMN1; SMN2GAA
SCHEMBL7511041 0.80 TBXAS1 (0.46) TBXAS1TAAR1FDPSSMN1; SMN2GAA
SCHEMBL24834446 0.80 GRIA2 (0.51) TBXAS1TAAR1FDPSALOX15FPR2
SCHEMBL3838965 0.80 GRIA2 (0.51) TBXAS1TAAR1FDPSALOX15FPR2
SCHEMBL781663 0.80 GRIA2 (0.51) TBXAS1TAAR1FDPSALOX15FPR2
SCHEMBL31544487 0.78
Hydrochloric Acid SCHEMBL11090438 0.77 GRIA1 (0.49) TBXAS1TAAR1FDPSALOX15FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
US-20230204605-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-06-29 US claimed
EP-2820038-B1 GLP-1 PRODRUGS NOVO NORDISK AS (DK) 2020-06-17 EP claimed
EP-3043810-B1 IMMUNE SYSTEM MODULATORS CANIMGUIDE THERAPEUTICS AB (SE) 2019-10-23 EP claimed
EP-3141284-B1 METHOD OF STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN ACID DERIVATIVE OREAL (FR) 2019-08-28 EP claimed
CN-104185639-B Prodrug of G L P-1 诺和诺德股份有限公司 2018-06-19 CN claimed
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
US-20170306504-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME CHAMPIONX LLC 2017-10-26 US claimed
EP-1991574-B1 OXYNTOMODULIN DERIVATIVES MERCK SHARP & DOHME (US) 2016-10-12 EP claimed
EP-2029237-B1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN ACID DERIVATIVE ORÉAL L (FR) 2016-10-12 EP claimed
CN-102389413-A Composition for treating diabetes and application thereof WANG QINGHUA (CA) 2012-03-28 CN claimed
US-20110183902-A1 PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION MERCK SHARP & DOHME CORP. (US) 2011-07-28 US claimed
US-20110111066-A1 METHOD AND COMPOSITION FOR IMPROVED ANABOLISM BIO-ENGINEERED SUPPLEMENTS AND NUTRITION, INC. (US) 2011-05-12 US claimed
EP-2305785-A1 Use of a carboxylic or amino compound as cleaning aid for hard surfaces and method of cleaning such hard surfaces Unilever N.V. (NL) 2011-04-06 EP claimed
US-20100300471-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN ACID DERIVATIVE L'OREAL S.A. (FR) 2010-12-02 US claimed
US-20100166675-A1 Pharmaceutical Composition for the Treatment of Type 1-Diabetes Wang, Qinghua (CA) 2010-07-01 US claimed
US-20100144617-A1 Oxyntomodulin Derivatives MERCK SHARP & DOHME LLC 2010-06-10 US claimed
CN-101389648-A Oxyntomodulin derivatives MERCK & CO INC ANGELETTI P IST (US) 2009-03-18 CN claimed
EP-1991574-A2 OXYNTOMODULIN DERIVATIVES Merck & Co., Inc. (US) 2008-11-19 EP claimed
WO-2007100535-A2 OXYNTOMODULIN DERIVATIVES MERCK & CO., INC. (US) 2007-09-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100300471-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN ACID DERIVATIVE KRT18, KLK5, HOGA1 TBXAS1 4009/4885PTPRA 4676/4885TAAR1 4102/4885
US-20100166675-A1 Pharmaceutical Composition for the Treatment of Type 1-Diabetes IAPP, GABRB1, GLP1R TBXAS1 3008/4885PTPRA 2893/4885TAAR1 1706/4885
US-20100144617-A1 Oxyntomodulin Derivatives GPR119, OGFRL1, OGFR TBXAS1 1163/4885PTPRA 2512/4885TAAR1 710/4885
US-20110183902-A1 PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION OGFR, GPR119, THOP1 TBXAS1 2288/4885PTPRA 2932/4885TAAR1 1064/4885
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 TBXAS1 4757/4885PTPRA 3259/4885TAAR1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.